Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications
Autologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs) that has Level A evidence, the effectiveness of which has been proven in three controlled clinical trials: ASSIST, ASTIS, and SCOT. Despite th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-02-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1102 |
| _version_ | 1797876665937821696 |
|---|---|
| author | O. B. Ovsyannikova L. P. Ananyeva O. A. Koneva L. A. Garzanova O. V. Desinova R. U. Shayakhmetova M. N. Starovoitova A. M. Lila |
| author_facet | O. B. Ovsyannikova L. P. Ananyeva O. A. Koneva L. A. Garzanova O. V. Desinova R. U. Shayakhmetova M. N. Starovoitova A. M. Lila |
| author_sort | O. B. Ovsyannikova |
| collection | DOAJ |
| description | Autologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs) that has Level A evidence, the effectiveness of which has been proven in three controlled clinical trials: ASSIST, ASTIS, and SCOT. Despite the positive results obtained with the use of this treatment option, the issues related to its tolerability and safety remain unresolved. The complications caused by obvious immunosuppression and higher frequency of infections are the main causes of death after autoHSCT for autoimmune diseases and occur mainly in the first month after treatment. Overall, the studies performed confirm the overall assessment of auto-HSCT as an effective and relatively safe treatment for severe SSs. |
| first_indexed | 2024-04-10T02:06:20Z |
| format | Article |
| id | doaj.art-6970a796db08439590e7c365a886818c |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:20Z |
| publishDate | 2021-02-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-6970a796db08439590e7c365a886818c2023-03-13T08:39:28ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2021-02-01151667210.14412/1996-7012-2021-1-66-722325Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complicationsO. B. Ovsyannikova0L. P. Ananyeva1O. A. Koneva2L. A. Garzanova3O. V. Desinova4R. U. Shayakhmetova5M. N. Starovoitova6A. M. Lila7ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииAutologous hematopoietic stem cell transplantation (auto-HSCT) is presently the only disease-modifying strategy for the treatment of systemic sclerosis (SSs) that has Level A evidence, the effectiveness of which has been proven in three controlled clinical trials: ASSIST, ASTIS, and SCOT. Despite the positive results obtained with the use of this treatment option, the issues related to its tolerability and safety remain unresolved. The complications caused by obvious immunosuppression and higher frequency of infections are the main causes of death after autoHSCT for autoimmune diseases and occur mainly in the first month after treatment. Overall, the studies performed confirm the overall assessment of auto-HSCT as an effective and relatively safe treatment for severe SSs.https://mrj.ima-press.net/mrj/article/view/1102системная склеродермияаутотрасплантациягемопоэтические стволовые клеткиосложненияпобочные эффекты |
| spellingShingle | O. B. Ovsyannikova L. P. Ananyeva O. A. Koneva L. A. Garzanova O. V. Desinova R. U. Shayakhmetova M. N. Starovoitova A. M. Lila Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications Современная ревматология системная склеродермия аутотрасплантация гемопоэтические стволовые клетки осложнения побочные эффекты |
| title | Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications |
| title_full | Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications |
| title_fullStr | Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications |
| title_full_unstemmed | Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications |
| title_short | Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications |
| title_sort | autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis part 2 safety and complications |
| topic | системная склеродермия аутотрасплантация гемопоэтические стволовые клетки осложнения побочные эффекты |
| url | https://mrj.ima-press.net/mrj/article/view/1102 |
| work_keys_str_mv | AT obovsyannikova autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications AT lpananyeva autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications AT oakoneva autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications AT lagarzanova autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications AT ovdesinova autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications AT rushayakhmetova autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications AT mnstarovoitova autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications AT amlila autologoushematopoieticstemcelltransplantationinthetreatmentofsystemicsclerosispart2safetyandcomplications |